Avanir Pharmaceuticals, Inc.
Pharmaceutical & medical device company payment data from CMS Open Payments.
Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $53.3M | 5,827 | 78.6% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $8.5M | 5,017 | 12.6% |
| Food and Beverage | $3.1M | 155,299 | 4.6% |
| Consulting Fee | $1.6M | 382 | 2.4% |
| Travel and Lodging | $1.1M | 3,850 | 1.6% |
| Space rental or facility fees (teaching hospital only) | $134,700 | 96 | 0.2% |
| Education | $6,543 | 716 | 0.0% |
| Gift | $4,377 | 3 | 0.0% |
| Charitable Contribution | $2,800 | 2 | 0.0% |
| Grant | $2,500 | 2 | 0.0% |
Payments by Type
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| 15-AVP-786-303 | $12.9M | 3 | 1,457 |
| 15-AVP-786-302 | $7.8M | 3 | 712 |
| 15-AVP-786-301 | $5.5M | 5 | 623 |
| 17-AVP-786-205 | $3.1M | 1 | 710 |
| 19-AVP-786-112 | $2.4M | 0 | 18 |
| 17-AVP-786-305 | $2.4M | 0 | 398 |
| 18-AVP-786-207 | $2.1M | 1 | 466 |
| 19-AVP-786-111 | $1.8M | 0 | 24 |
| 18-AVP-786-108 | $1.5M | 0 | 24 |
| 17-AVP-825-301 | $1.5M | 2 | 217 |
| 15-786-303 | $1.3M | 0 | 127 |
| 18-AVP-786-107 | $1.2M | 0 | 20 |
| 20-AVP-786-306 | $1.1M | 0 | 277 |
| EfficacySafetyTolerabilityAVP-786ForTreatment AgitationinPatientsW/Dementia of the Alzheimer's Type | $1.1M | 3 | 170 |
| 19-AVP-786-110 | $820,788 | 0 | 10 |
| 17-AVP-786-106 | $696,141 | 0 | 24 |
| 17-AVR-135 | $693,753 | 0 | 33 |
| 15-786-302 | $689,522 | 0 | 64 |
| 19-AVP-786-109 | $687,285 | 0 | 6 |
| 15-AVP-786-202 | $659,747 | 1 | 47 |
| 15-786-301 | $627,761 | 0 | 85 |
| 20-AVP-786-307 | $596,750 | 0 | 176 |
| 19-AVP-786-108 | $557,850 | 0 | 3 |
| 19-AVP-786-108, 19-AVP-786-109, 19-AVP-786-110, 19-AVP-786-111, 19-AVP-786-112, 19-AVP-786-113 | $353,750 | 0 | 1 |
| 17-AVP-786-206 | $272,524 | 0 | 56 |
| Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Residual Schizophrenia | $233,030 | 0 | 18 |
| Rat model of behavioral aspects of traumatic brain | $98,540 | 0 | 2 |
| Prevalence of Pseudobulbar Affect Symptoms in Professional Fighters and association with neurologica | $90,744 | 0 | 1 |
| AVS-P2-028, AVS-P9-189, AVS-P7-303, AVS-P3-114 | $79,250 | 0 | 1 |
| 15-AVP-706-202 | $73,270 | 0 | 1 |
Payments by Medical Specialty
Top Paid Doctors — Page 6
| Doctor | Specialty | Location | Total | 2017 |
|---|---|---|---|---|
| Wade Cooper, Do, DO | Neurology | Ann Arbor, MI | $15,989 | $0 |
| Dr. Jennifer Sampang, Ph.d, Msn, PH.D, MSN | Nurse Practitioner | Crestview Hills, KY | $15,814 | $0 |
| Dr. Sachin Mehta, M.d, M.D | Physical Medicine & Rehabilitation | Indianapolis, IN | $15,716 | $0 |
| Dr. Alexander Mauskop, Md, MD | Specialist | New York, NY | $15,433 | $0 |
| Dr. Jeffrey Mattes, Md, MD | Psychiatry | Princeton, NJ | $15,411 | $0 |
| Eric Eross, Do, DO | Specialist | Phoenix, AZ | $15,340 | $0 |
| Wendell Helveston, Md, MD | Neurology | Jackson, MS | $15,221 | $0 |
| Arpana Edala, Md, MD | Geriatric Medicine | Little Rock, AR | $15,100 | $0 |
| Nathan Bennett, M.d, M.D | Family Medicine | Pittsburgh, PA | $14,912 | $0 |
| Dr. Alan Rapoport, M.d, M.D | Neurology | Los Angeles, CA | $14,419 | $0 |
| Dr. Sara Sacco, M.d, M.D | Specialist | Matthews, NC | $13,684 | $0 |
| Dr. John Cochran, M.d, M.D | Neurology | Alexandria, VA | $13,661 | $0 |
| Tulio Bertorini, Md, MD | Neurology | Memphis, TN | $13,608 | $0 |
| P. Christopher Gottschalk, M.d, M.D | Neurology | Fairfield, CT | $13,584 | $0 |
| Dr. Matthew Berger, Md, MD | Psychiatry | Moosic, PA | $13,397 | $0 |
| Gary Pattee, M.d, M.D | Neurology | Lincoln, NE | $13,387 | $0 |
| Terrence Norton, M.d, M.D | Psychiatry | Platteville, WI | $13,226 | $0 |
| Dr. Randolph Evans, Md, MD | Neurology | Houston, TX | $13,186 | $0 |
| Gary Ruoff, M.d, M.D | Family Medicine | Kalamazoo, MI | $13,161 | $0 |
| Shiva Natarajan | Neurology | Germantown, TN | $12,899 | $0 |
| Robert Krug, Md, MD | Physical Medicine & Rehabilitation | Hartford, CT | $12,826 | $0 |
| Dr. Merle Diamond, Md, MD | Internal Medicine | Chicago, IL | $12,818 | $0 |
| Dr. John Fritz, Do, DO | Family Medicine | Jersey City, NJ | $12,644 | $0 |
| Kamal Bijanpour, M.d, M.D | Addiction Psychiatry | Long Beach, CA | $12,602 | $0 |
| Victor Sobolewski, Do, DO | Family Medicine | Lakewood, WA | $12,469 | $0 |
Top Products
- NUEDEXTA $10.7M
- ONZETRA Xsail $1.7M
Associated Products (4)
- NUEDEXTA $12.2M
- ONZETRA Xsail $1.7M
- Nuedexta $662,629
- ONZETRA $13,689
Payment Categories
- Food & Beverage $3.1M
- Consulting $1.6M
- Travel & Lodging $1.1M
- Research $53.3M
About Avanir Pharmaceuticals, Inc.
Avanir Pharmaceuticals, Inc. has made $67.8M in payments to 32,877 healthcare providers, recorded across 171,194 transactions in the CMS Open Payments database. In 2022, the company paid $2.5M. The top product by payment volume is NUEDEXTA ($10.7M).
Payments were distributed across 231 medical specialties. The top specialty by payment amount is Psychiatry ($4.5M to 3,474 doctors).
Payment categories include: Food & Beverage ($3.1M), Consulting ($1.6M), Research ($53.3M), Travel & Lodging ($1.1M).
Avanir Pharmaceuticals, Inc. is associated with 4 products in the CMS Open Payments database, including NUEDEXTA, ONZETRA Xsail, and Nuedexta.